WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Implantable Drug Delivery System

***Mr. Pawar Vaibhav Achyutrao[1], Mr. S. R. Sakhare[2]***

**[1]B. Pharmacy Final Year Student, Latur College of Pharmacy, Hasegaon. Srtmun.**
**[2]Assit. Professor Dept. of Pharmaceutics, Latur College of Pharmacy, Hasegaon. Srtmun.**

**ABSTRACT :-**

This paper examines the limits of standard drug delivery systems, which lack control over drug release patterns and absorption at the target site, resulting in undefined drug concentrations in plasma. To solve this issue, the study focuses on implantable drug delivery systems (IDDS), emphasizing their formulation, preparation, evaluation parameters, and future possibilities.

IDDS provide regulated medication administration at precise implantation sites, decreasing drug concentrations and side effects while enhancing patient compliance. These devices offer focused local drug delivery at a consistent pace, decreasing drug dosage and improving therapeutic efficacy. Some implants are still in the early stages of development and will require extensive clinical testing before being approved for usage. Drug delivery methods have evolved throughout time to maximize drug product therapeutic qualities, safety, and reliability.

IDDS exemplify IDDS) are examples of such treatment systems. The main emphasis of this analysis is the investigation of currently existing implanted medication delivery devices. The primary benefits of these systems include focused local medication deliver try at a consistent rate, fewer pharmaceuticals required to treat the disease state, minimization of potential side effects, and improved therapeutic efficacy. Because to the invention of such prolonged release formulations, it is now possible to provide unstable medications once a week to once a year, which formerly needed frequent daily administration. Preliminary trials using these devices have demonstrated that they are more effective than traditional therapy approaches. However, one disadvantage of these recently designed medication delivery systems is that their cost-to-benefit ratio (cost/benefit) is low.

**Keywords**:- Implantable drug delivery, modulated drug delivery, implants, drug delivery systems, , recent technologies.

## Introduction :-

The pharmaceutical field grapples with intricate challenges in achieving effective drug delivery, particularly for orally administered drugs. Ensuring a drug's therapeutic effectiveness demands a fine balance between safeguarding it from degradation in the gastrointestinal tract, facilitating absorption, and evading hepatic enzymatic breakdown. Additionally, the control of drug absorption and elimination is pivotal to maintain therapeutic blood levels while optimizing the quantity of the drug reaching its site of action. To tackle these complexities, two primary strategies emerge: modifying drug molecules chemically and crafting specialized formulations for controlled release.

Oral controlled release dosage forms offer sustained efficacy, though their drawback lies in the extended transit time through the gastrointestinal tract. When oral delivery is unfeasible, especially for drugs sensitive to GIT conditions, alternative routes like parenteral administration become pivotal. This review explores diverse drug delivery strategies, emphasizing protection and controlled release for oral administration while enhancing therapeutic effects and minimizing adverse consequences. The delivery of therapeutically active agents poses ongoing challenges in pharmaceutical sciences. Intravenous administration, while offering rapid drug action, necessitates frequent injections due to short drug activity durations. Injectable controlled-release dosage forms hold potential for sustained drug effects and commercial viability, particularly when ensuring efficacy and safety. Topical drug administration faces limitations due to drug characteristics and impermeable skin layers, whereas implantable drug delivery devices offer unique advantages. Subcutaneously implantable devices, in particular, include a retrievable mechanism, promising improved drug delivery. To accommodate various agents with diverse properties and enhance release mechanisms, additives are increasingly used in current implantable devices, offering flexibility in drug delivery methods. While oral delivery remains popular, alternative approaches like pulmonary, infusion, and implantable systems address specific drug delivery challenges. For instance, macromolecules may degrade in the gastrointestinal tract, making oral administration unsuitable. Injectable drug delivery, while effective, presents patient discomfort and compliance issues. Fully implantable drug delivery devices emerge as attractive options, ensuring controlled drug delivery with precision, accommodating diverse therapeutic patterns. Various delivery methods, including pulmonary, transdermal, intravenous, subcutaneous, and implantable systems, have been developed for situations where oral delivery falls short. Implantable drug delivery devices gain significance when strict adherence to drug regimens is essential, offering controlled delivery without frequent medical intervention. Current drug delivery implants fall into two main categories: passive or active systems. Passive systems like polymer depots maintain consistent drug release, while conventional programmable devices allocate substantial space for long-lasting batteries. Refilling typically occurs every 10 weeks via

transdermal injection. This research aims to enhance the volume efficiency of implantable drug delivery devices by replacing traditional batteries with smaller, rechargeable ones. Ideally, recharging coincides with drug reservoir refilling, with DC recharge capability offering suitability for implantable devices. Over the past two decades, controlled drug delivery has confronted significant challenges. Sustained, zero -order drug release over extended periods has been achieved through various techniques, such as osmotically driven pumps, controllable swelling matrices, diffusion, erosion rates, non-uniform drug profiles, and multi-layered matrices .the second challenge pertains to delivering therapeutic molecules or proteins in pulsatile or responsive manners. Approaches include designing systems for predetermined release times or sequences and developing systems that respond to environmental changes.

Responsive systems adapt drug delivery rates to stimuli like specific molecules, magnetic fields, electric fields, ultrasound, light, temperature, and mechanical forces.

## Characteristics of Implantable Drug Delivery Systems:

**1.Environmental Resilience**: Should withstand various environmental conditions.

**2. Biodegradability**: Ideally, should be bio absorbable, allowing gradual breakdown.

**3. Sterility**: Must maintain sterility to ensure safe implantation.

**4. Bio stability**: Should remain stable within the body's biological environment.

**5. Enhancing Patient Adherence**: Reducing the frequency of drug administration throughout the treatment period can enhance patient adherence.

**6. Controlled Release**: Delivering the drug in a controlled manner aids in improving effectiveness while minimizing side effects.

**7. Accessibility for Medical Intervention**: Should be easily retrievable by medical professionals for potential treatment termination.

**8. Cost-Effective and Easy to Manufacture**: Ideally, these systems should be cost effective and straight forward to produce.

**9. Mechanical Strength**: Should possess good mechanical strength for durability.

**10. Non-Invasive**: Should not require surgical procedures for implantation, if possible.

**11. Reduced Dosing Frequency**: Lowering dosing frequency is essential to enhance patient compliance, ensuring consistent drug release throughout the treatment duration.

## Advantages of Implantable Drug Delivery System:

The advantages of implantation therapy include.

1. **Convenience**: -Effective concentration of drug in the blood can be maintained for longer period of time by techniques such as continuous intravenous infusion or repeated injections. On the other hand, under these treatments patients are regularly required to visit hospital throughout administration for uninterrupted medical monitoring.

A short-acting medicine worsens the condition, as the quantity of injections or the infusion rate need to be increased to maintain a therapeutically effective level of the drug. On the other hand, implantation treatment permits patients to get medication outside the hospital setting with marginal medical observation. implantation The treatment is also characterized by a lower incidence of Problems related to infections compared to Infusion system based on an indwelling catheter.

2. **Improved drug delivery**: - Drugs are distributed locally or systemically Disturbances in metabolism and blood circulation due to metabolism are minimized. Biological barrier. For example, the active ingredients bypass the gastrointestinal tract and liver. bypass effect Beneficial for light medicine. Inactivated or poorly absorbed in the gastrointestinal and/or gastrointestinal tract Liver before systemic distribution [1] in the bloodstream. In contrast, methods like continuous.

3. **Prolonged Concentration**: This system allows for the sustained maintenance of effective drug concentrations intravenous infusions or repeated injections necessitate frequent hospital visits for continuous medical monitoring. Short-acting medications can worsen the condition, leading to an increased need for injections or infusion rates to maintain therapeutic drug levels. Implantation, however, enables patients to receive medication outside of the hospital, with minimal medical supervision.

4. **Compliance** :- By making it possible to reduce or completely eliminate Improving patient-related medication compliance Extremely. However, patients may forget to take their medication. Implant drug delivery is implant independent Input from the patient. Occasionally, periodic replenishment may be necessary implants, but despite this limitation, patients Less involved in providing needed services medicine.

5. **Flexibility** : When choosing materials and manufacturing processes, Drug loading degree, drug release rate, etc. Considerable flexibility is possible. of From a regulatory perspective, this is a new product Market protection for pharmaceuticals can be expanded .An additional 5 years (for new drug registrations)or 3 years(for existing drugs) [18-21].

## Disadvantages of Implantable Drug Delivery System:-

While implantable drug delivery systems offer significant advantages, they also have some disadvantages:

**1. Invasive**: In certain cases, a major surgical procedure is necessary for implantation, leading to scarring at the implant site and discomfort. Skilled personnel are required for device implantation.

**2. Termination**: Non-biodegradable polymeric implants need surgical removal from the body after treatment completion.

**3. Device Failure Risk**: If the implant malfunctions during treatment, it necessitates surgical removal from the patient's body.

**4. Limited to Potent Drugs**: Implants are usually kept small to minimize patient discomfort, limiting their drug-loading capacity. They are primarily suitable for potent medications.

**5. Possibility of Drug Reactions**: Dose dumping at the implant site can lead to severe adverse reactions

## Formulation of implantable drug delivery systems:-

Implantable drug delivery systems are an important area of research and development in the field of medicine. These systems are designed to provide controlled and sustained release of drugs within the body, offering several advantages such as improved patient compliance and reduced side effects.

The formulation of implantable drug delivery systems involves several key steps:

**1. Drug Selection**: The first step is to select the appropriate drug for the intended therapeutic purpose. Factors such as drug solubility, stability, and release kinetics must be considered.

**2. Polymer Selection**: Biocompatible and biodegradable polymers are commonly used to encapsulate the drug. Polymers like PLGA (poly(lactic-co-glycolic acid)) are often chosen due to their versatility.

**3. Drug-Polymer Compatibility**: Ensuring compatibility between the drug and polymer is crucial to maintain drug stability and achieve controlled release.

**4. Formulation Design**: The drug and polymer are combined to create a formulation. This can be done using various techniques, such as solvent evaporation or hot-melt extrusion, depending on the chosen materials.

**5. Controlled Release Mechanism**: Implantable systems can be designed for variousrelease mechanisms, including diffusion-controlled, erosion-controlled, or osmotic controlled.

The choice depends on the desired release profile.

**6. Biocompatibility and Safety**: The formulation must be thoroughly tested for biocompatibility and safety to ensure it won't cause harm when implanted in the body.

**7. Implantation Site Selection**: Depending on the therapeutic target, the appropriate site for implantation must be chosen. For example, subcutaneous, intramuscular, or intraocular implantation may be considered.

**8. Release Kinetics Optimization**: The release rate of the drug must be carefully controlled to achieve therapeutic efficacy. This may involve adjusting the polymer composition or implant geometry.

**9. Quality Control and Manufacturing**: Stringent quality control measures are necessary during manufacturing to ensure consistency and safety of the implantable drug delivery systems.

**10. Regulatory Approval**: Implantable drug delivery systems must undergo rigorous testing and seek regulatory approval before they can be used in clinical settings.

**11. Clinical Trials**: Clinical trials are conducted to evaluate the safety and efficacy of the implantable system in humans.

**12. Post-Market Surveillance**: Continuous monitoring and evaluation of the system's performance and any potential adverse effects in real-world use.

Research in this field is ongoing, and advancements in materials science, Nano technology, and biotechnology continue to drive innovation in the formulation and development of implantable drug delivery systems.




Fig:-1




Fig.2

## Method of preparation of implantable drug delivery systems:-

Implantable drug delivery systems are designed to release drugs gradually over an extended period of time. Here are some common ways to prepare them.

**1. Encapsulation**: Drugs are encapsulated in biocompatible materials such as polymers and lipids. As the material breaks down over time, the active ingredients are released. Examples of this include microspheres and liposomes.

**2. Reservoir systems**: These consist of a drug reservoir surrounded by a semi-permeable membrane. The active ingredient diffuses through the membrane in a controlled manner. One example is an osmotic pump.

**3. Biodegradable Implants**: Biodegradable polymers are used to create implantable devices that gradually break down and release drugs. This eliminates the need for removal surgery.

**4. Electrospinning**: In this technique, a polymer solution is electrostatically spun to form nanofibers. Incorporation of drugs into these fibers allows for controlled release when the fibers dissolve.

**5. Incorporation into devices**: Drugs can be incorporated into medical devices such as stents and orthopedic implants that slowly release the drug locally over time.

**6. Injectable Depots**: Injectable implants, such as subcutaneous pellets, are surgically implanted and slowly release the drug as they dissolve or degrade.

**7**. **Nanotechnology**: Nanoparticles such as nano capsules and nano spheres can encapsulate drugs for controlled release. These particles can be manipulated to release drugs based on environmental factors or stimuli.

**8. Microfabrication**: Microfabrication techniques such as micromachining and 3D printing can be used to manufacture precise drug delivery systems for targeted therapies. Each method has its advantages and is selected based on factors such as drug properties, desired release profile, and patient needs. The choice of method can impact the efficacy and safety of implantable drug delivery systems.

## Therapeutic Applications of IDDS:-

**Ocular disease:-**

Numerous different implantable systems have been estimated to deliver sustained ocular delivery. These comprise membrane-controlled devices, implantable infusion systems and implantable silicone devices. Ocular insert (ocusert) having pilocarpine base and alginic acid in a drug reservoir surrounded by a release-rate controlling ethylene-vinyl acetate membrane is an example of the membrane-controlled system[39-41]. The ocusert system offers an initial rupture followed by a near zero order transport of pilocarpine[42] at 20 or 40 μg/h for a span of seven days. The device is well tolerated in adults, with suitable control of intraocular pressure and minimal side effects[43-46]. However it looks to be poorly tolerated in the geriatric patients where most of the therapeutic requirement exists .Implantables evaluated for ocular cancer management include silicone rubber balloon having an antineoplastic agent.

**Contraception:-**

Norplant a sub-dermal implant for long-lasting transport of the contraceptive agent Levonorgestrel recently been approved for marketing by the FDA. The device consists of six silicone membrane capsules each having about 36 mg of levonorgestrel. The capsules are placed sub-dermally on the inside of the upper arm or the forearm in a fan-shaped pattern through a trocar from a single trocar entry point. Clinically, Norplant users have a net pregnancy rate of below 1.5 in 100 women at 4 years. At the end of 4 years 42 % of the women continued with the technique representing acceptability comparable with other techniques. Other polymer-based contraceptive methods studied include vaginal rings, usually made of silicone rubber, used for 3 to 76 months, usually with weekly removal, left monthly to allow for periods. Progest acert is an ethylene-vinyl acetate copolymer, consisting of extended injectable microspheres or rods made of a biodegradable polymer and an antibiotic in the body that lasts for one year [41].

**Dental Applications: -**

Polymer implants have been evaluated in many dental applications, including the long-term use of fluoride as an antibiotic and antibiotic. Stannous fluoride is incorporated into many types of dental cements for fluoride delivery. Other tools are dispersed in hydrogels of copolymers of hydroxyethyl methacrylate and methyl methacrylate coated with a layer of the same copolymer in different drug release rate ratios. An attached device approximately 8mm long and containing 42mg of fluoride in its core. It is designed to release 0.5 mg of fluoride per day for 30 days onto the oral surface of maxillary first molars [47-49].

**Immunization: -**

Polymeric plant compounds have been studied to provide better protection against disease than antibiotics. The idea here is pulsatile or continuous delivery of antigen over a long period of time.

Wise et al. evaluated immunization efficiency of ethylene-vinyl acetate copolymer pellets having bovine serum albumin as model antigen. The immune response was comparable to that achieved by two injections of bovine serum albumin in complete Freund's adjuvant (Freund's adjuvant is an o/w emulsion containing bacteria).

**Cancer:-**

Silicone rod implants analogous to those used for delivery of levon orgestrone have been evaluated for delivery of ethinyl estradiol or testosterone propionate in persons with prostate cancer. Lupron depot produced by Takeda chemical industries is an implantation system providing one month depot release of leuprolide acetate, a synthetic analogue of the gonadotropin-releasing hormone (Gh-RH). The implant containing biodegradable microspheres made from poly -lactic – glycolic copolymer at 1:1 compositions having 10% leuprolide acetate for the management of prostate cancer. Zoladex produced by ICI Pharma provides one month depot release of goserelin acetate from a biodegradable implantable rod for the management of prostate cancer.

**Narcotic antagonists:-**

Naltrexone has been comprehensively evaluated in implant from long term delivery of narcotic antagonists. Naltrexone freebases its hydrochloride or the pamoate acid salt has been formulated in a various polymers and dosage forms for prolonged narcotic antagonist activity.

**Other applications:-**

Various insulin delivery systems have been formulated and evaluated for a biofeedback approach and have been described before. These are biofeedback controlled system, where the drug release rate is reliant on the body's requirement for the drug at a specified time.

From a therapeutic perspective these systems may come closest to reproducing the release from a gland for example the pancreas. Various mechanisms have been employed to attain self regulated delivery[2, 41]. The above mentioned applications are few examples of therapeutic applications of implantable drug delivery system.

## FUTURE PROSPECTS

At present important exploration is being conducted in the region of implantable medicine delivery systems. Despite this fact, important work is still needed in the regions of biodegradable and biocompatible substances, the

kinetics of medicine release, and more enhancement of present systems before numerous of these medications can

be used. In the future, scientists remain expectant that numerous of these systems can be prepared with stylish zero order release kinetics biographies, in vivo, over long times, allowing for dragged use in constantly sick

drugs are continuously being set. Several of these specifics are developed from proteins and peptides which are veritably unstable when taken through oral route. By using new types of prolonged- release medicine delivery systems, delivering similar medicines at constant rates will be possible over aprolonged period of time and will count the necessity for multiple dosing. It's anticipated that in the forthcoming times, enhancement of new implantable systems will help bring reduction of medicine treatment, increase the effectiveness of medicines, and enhance patient compliance( 50- 52)

## CONCLUSION:-

These days, implantable drug delivery is one of them. Technology areas that are often Over looked Development of new drug delivery through formulations, Research and development of many pharmaceutical products. Embedded drug delivery technology makes this possible Reduce the frequency of patient-controlled dosing Provide specific connections. many Products using implant delivery technology are Used for many therapeutic applications. B. Dental, eye, and tumor diseases. the same as Implant materials, biocompatibility issues It is necessary to investigate the formation of Peri-implant fiber capsule and if necessary Erosion base devices , potentially toxic or Immunogenicity of polymer by-products deterioration. In addition , as a practical method, Control drug delivery trigger externally For this we need to develop a delivery system Being practical. In addition to these issues, Potential therapeutic effects of pulse administration In treatment, current high levels of Interest in this field will continue Bringing major advances in the field of control drug delivery. A huge number of companies Involved in the development of new drug administration The growth in systems is reflected in the growth in the number of systems Commercial products and number of patents Recently granted. tomorrow's medicine It's definitely going to be more challenging Delivery system and drug development Scientists need to prepare for difficult tasks in advance .

**REFERENCES:-**

1]. Chien Yie W; Novel Drug Delivery Systems, Marcel Dekker Inc.;1992, 2nd Ed, 269.

[2]. Vyas SP and Khar Roop K; Controlled Drug Delivery Concepts and Advances, Vallabh Prakashan (Delhi);2008, 1st Ed, 450-459.

[3]. Langer R; Where a Pill Won't Reach, Scientific American; 2003, 288(4): 50– 57

[4]. Hassenbusch SJ, Portenoy RK, Cousins M, et al;Poly analgesic Consensus Conference 2003: An Update on the Management of Pain by Intraspinal Drug Delivery: Report of an Expert Panel, J. Pain Symptom Manage; 2004, 27(6):540-563.

[5]. Carmichael M; The Changing Science of Pain, Newsweek; June 4, 2007, 40-47.

[6]. Boveja, et al; Method and System for Providing Pulsed Electrical Stimulation to Provide Therapy for Erectile/Sexual Dysfunction, Prostatitis, Prostatitis Pain, and Chronic Pelvic Pain, U.S. Patent; Feb. 12, 2008, Patent No.7330762

[7] Wentworth JS, Paterson CA, Wells JT,Tilki N,Gray RS, McCartney MD; Collagen Shields Exacerbate Ulceration of Alkali-burned Rabbit Corneas, Arch Ophthalmol; 1993, 111:389-392.

[8]. Lamberts DW, Pavan-Langston D, Chu W; A Clinical Study of Slow-Releasing Artificial Tears; Ophthalmology; 1978, 85:794-800.

[9]. BawaR, Dais M, Nandu M, Robinson JR; New Extended Release Ocular Drug Delivery System: Design, Characterization and Performance Testing of Minidisc Inserts, ProcIntSymp Control \RelBioact Mater; 1988,15:106a-b.

[10]. Koka S; The Implant-Mucosal Interface and Its Role in the Long-Term Success of Endosseous Oral Implants: A Review of the Literature,Int J Prosthodontics; 1998,11(5):421-432.

[11]. Sennerby L, Roos J; Surgical Determinants of Clinical Success of Osseointegrated Oral Implants: A Review of the Literature,Int J Prosthodontics;1998, 2(5): 408.

[12]. RahmanA,Dedi K, Samuel Z, Rashid S, Solakoglu O, Beres F, Cooper LF;Immediate Placement and Immediate Provisionalization of ITI Implants in Maxillary Non-Restorable Single Teeth. A Preliminary Report; Jun-2004, 13(2):6671.

[13]. Gupta PK, Hung CT, and Perrier DG; Quantitation of the Release of Doxorubicin Form Colloidal Dosage Forms using Dynamic Dialysis, J Pharm Sci.; 1987, 76:141–145.

[14]. Robinson DH, and Sampath S; Release Kinetics of Tobramycin Sulphate from Polymethylmethacrylate Implants, Drug Dev. Ind. Pharm;1989, 15: 2339–2357.

[15]. Vyas SP and KharRoop K; Controlled Drug Delivery Concepts and Advances, Vallabh Prakashan (Delhi);2008,1st Ed, 473-474

[16]. Katz IM, Blackman WM; A Soluble SustainedRelease Ophthalmic Delivery Unit, Am JOphthalmol; 1977, 83:728-734.

[17]. W.A Check. New drugs and drug-delivery systems in the year 2000. AM J Hosp Pharm 1984; 41:1536-47.

[18]. Chien Yie W. Novel drug delivery systems. Marcel Dekker Inc 1982; 1:1-816.

[19]. Abhinandan AA, Vikas RA, Pallavi SJ and Rajshekhar MC. Formulation and Evaluation of Novel Biodegradable Sustain Released Matrix Implant of Gentamicin Sulphate. Res J Pharm Biol Chem Sci 2018; 9:451-463.

[20]. Chien Yie W. Novel drug delivery systems, Marcel Dekker Inc 1992.

[21]. Seaton's MF and Salminen L. Ocular Inserts for topical Delivery. Adv Drug del Rev 1995; 16:95-106.